Clinical case of complications of immunotherapy – encephalitis
- Authors: Lyadova M.A.1, Kuchevskaya O.A.1, Kulikova E.A.1
-
Affiliations:
- City Clinical Oncology Hospital №1
- Issue: Vol 25, No 1 (2023)
- Pages: 140-144
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/132808
- DOI: https://doi.org/10.26442/18151434.2023.1.202168
- ID: 132808
Cite item
Full Text
Abstract
Nowadays, checkpoint inhibitors are widely used in the treatment of various types of cancer. However, its’ use is often accompanied by the development of immune-mediated adverse events (IAEs) of various systems and organs. Aim – description of the features of the development of encephalitis during the treatment of small cell lung cancer (SCLC) using checkpoint inhibitors. There is a clinical case of a patient, who is receiving immunotherapy, with small cell carcinoma of the upper lobe of the left lung, stage IVA, cT2bN2M1a. The patient sought medical help in connection with complaints of an episode of memory loss, difficulty in remembering new information. Based on the clinical picture and examination data, a limbic encephalitis was diagnosed. Immune-related adverse events might affect any organ during all the period of therapy with checkpoint inhibitors. Physicians shall be aware of the risk of encephalitis development related to this type of anti-cancer therapy.
Full Text
##article.viewOnOriginalSite##About the authors
Marina A. Lyadova
City Clinical Oncology Hospital №1
Email: dr.lyadova@gmail.com
ORCID iD: 0000-0002-9558-5579
SPIN-code: 8220-2854
Cand. Sci. (Med.), City Clinical Oncology Hospital №1
Russian Federation, MoscowOlesya A. Kuchevskaya
City Clinical Oncology Hospital №1
Email: olesya.kuchevskaya@mail.ru
ORCID iD: 0000-0002-1568-8683
Oncologist, City Clinical Oncology Hospital №1
Russian Federation, MoscowEvgeniya A. Kulikova
City Clinical Oncology Hospital №1
Author for correspondence.
Email: kulikovaEA14@zdrav.mos.ru
ORCID iD: 0000-0002-0319-4934
SPIN-code: 2884-4803
Department Head, City Clinical Oncology Hospital №1
Russian Federation, MoscowReferences
- Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807-21. doi: 10.1038/s41423-020-0488-6
- Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol. 2021;16:223-49. doi: 10.1146/annurev-pathol-042020-042741
- Chhabra N, Kennedy J. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. J Med Toxicol. 2021;17(4):411-24. doi: 10.1007/s13181-021-00833-8
- Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367(6477):eaax0182. doi: 10.1126/science.aax0182
- Corrales L, Gajewski TF. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. Cytokine. 2016;77:245-7. doi: 10.1016/j.cyto.2015.08.258
- Jenkins MK. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med. 1987;165(2):302-19. doi: 10.1084/jem.165.2.302
- Yshii LM, Hohlfeld R, Liblau RS. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol. 2017;13(12):755-63. doi: 10.1038/nrneurol.2017.144
- Gibson HM, Hedgcock CJ, Aufiero BM, et al. Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter. J Immunol. 2007;179(6):3831-40. doi: 10.4049/jimmunol.179.6.3831
- Zheng Y, Josefowicz SZ, Kas A, et al. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 2007;445(7130):936-40. doi: 10.1038/nature05563
- Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201-17. doi: 10.1084/jem.20112741
- Granier C, De Guillebon E, Blanc C, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017;2(2):e000213. doi: 10.1136/esmoopen-2017-000213
- Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord. 2018;11:1756286418799864. doi: 10.1177/1756286418799864
- Kyi C, Carvajal RD, Wolchok JD, Postow MA. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer. 2014;2(1):35. doi: 10.1186/s40425-014-0035-z
- Sato K, Akamatsu H, Murakami E, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer. 2018;115:71-4. doi: 10.1016/j.lungcan.2017.11.019
- Bomze D, Hasan Ali O, Bate A, Flatz L. Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden. JAMA Oncol. 2019; 5(11):1633-5. doi: 10.1001/jamaoncol.2019.3221
- Balachandran VP, Łuksza M, Zhao JN, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551(7681):512-6. doi: 10.1038/nature24462
- Weiss MD, Luciano CA, Semino-Mora C, et al. Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology. 1998;51(6):1738-41. doi: 10.1212/wnl.51.6.1738
- Gerdes LA, Held K, Beltrán E, et al. CTLA4 as immunological checkpoint in the development of multiple sclerosis: CTLA4 and MS. Ann Neurol. 2016;80(2):294-300. doi: 10.1002/ana.24715
- Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4(12):1721-8. doi: 10.1001/jamaoncol.2018.3923
- Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563-80. doi: 10.1038/s41571-019-0218-0
- Dubey D, David WS, Reynolds KL, et al. Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Ann Neurol. 2020;87(5):659-69. doi: 10.1002/ana.25708
- Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, et al. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med. 2019;25(8):1243-50. doi: 10.1038/s41591-019-0523-2
- Johnson DB, Manouchehri A, Haugh AM, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019;7(1):134. doi: 10.1186/s40425-019-0617-x
- Fan S, Ren H, Zhao L, et al. Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature. Asia Pac J Clin Oncol. 2020;16(6):291-8. doi: 10.1111/ajco.13375
- Schneider S, Potthast S, Komminoth P, et al. PD-1 checkpoint inhibitor associated autoimmune encephalitis. Case Rep Oncol. 2017;10(2):473-8. doi: 10.1159/000477162
- Richard K, Weslow J, Porcella SL, Nanjappa S. A case report of steroid responsive nivolumab-induced encephalitis. Cancer Control. 2017;24(5):1073274817729069. doi: 10.1177/1073274817729069
- Проценко С.А., Антимоник Н.Ю., Баллюзек М.Ф., и др. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2022;12(3S2-2):203-41 [Procenko SA, Antimonik NJu, Balljuzek MF, et al. Practical Guidelines for the Management of immune-related adverse events. Zlokachestvennie opuholi: Prakticheskie rekomendacii RUSSCO #3s2. 2022;12(3S2-2):203-41 (in Russian)]. doi: 10.18027/2224-5057-2022-12-3s2-203-241
- Conry RM, Sullivan JC, Nabors LB. Ipilimumab-induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res. 2015;3(6):598-601. doi: 10.1158/2326-6066.CIR-15-0035
- Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep. 2016;bcr2016215012. doi: 10.1136/bcr-2016-215012
- Schmitt SE, Pargeon K, Frechette ES, et al. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012;79:1094-100. doi: 10.1212/WNL.0b013e3182698cd8
- Leitinger M, Varosanec MV, Pikija S, et al. Fatal necrotizing encephalopathy after treatment with nivolumab for squamous non-small cell lung cancer: case report and review of the literature. Front Immunol. 2018;9:108. doi: 10.3389/fimmu.2018.00108
- Vitt JR, Kreple C, Mahmood N, et al. Autoimmune pancerebellitis associated with pembrolizumab therapy. Neurology. 2018;91(2):91-3. doi: 10.1212/WNL.0000000000005781
- Weil AA, Glaser CA, Amad Z, Forghani B. Patients with suspected herpes simplex encephalitis: rethinking an initial negative polymerase chain reaction result. Clin Infect Dis. 2002;34(8):1154-7. doi: 10.1086/339550